Category: 3. Business

Sky Metals Limited (ASX:SKY) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Sky Metals Limited engages in the exploration and development of mineral resources in Australia. On 30 June 2025, the AU$60m market-cap company posted a loss of AU$3.2m for its most recent financial year. As path to profitability is the topic on Sky Metals’ investors mind, we’ve decided to gauge market sentiment. We’ve put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Sky Metals is bordering on breakeven, according to some Australian Metals and Mining analysts. They anticipate the company to incur a final loss in 2027, before generating positive profits of AU$4.0m in 2028. So, the company is predicted to breakeven approximately 3 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow 88% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of Sky Metals’ upcoming projects, though, take into account that by and large metals and mining companies, depending on the stage of operation and metals mined, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Check out our latest analysis for Sky Metals

One thing we’d like to point out is that Sky Metals has no debt on its balance sheet, which is rare for a loss-making metals and mining company, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

There are key fundamentals of Sky Metals which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Sky Metals, take a look at Sky Metals’ company page on Simply Wall St. We’ve also compiled a list of pertinent aspects you should further examine:

We have exciting news to share. Three of our landmark projects have been selected as finalists at the prestigious MIPIM Asia 2025 Awards, each competing in distinct categories. This recognition reflects our unwavering commitment to placemaking across Asia.

Our Finalist Projects:

18 Cross, Singapore – Best Urban Regeneration Project
This transformation of the former Cross Street Exchange has created a thriving destination in Singapore’s CBD. The14,000 sqm development seamlessly merges a contemporary 15-storey Grade A office tower with heritage shophouses, achieving both Green Mark and WELL Platinum certifications. With its biophilic design, energy-efficient systems, and EV infrastructure, 18 Cross exemplifies how thoughtful regeneration can honour the past while building for the future.

Taichung D‑ONE, Taiwan – Best New Mega Development Project
Taichung D‑ONE is a visionary 47,000 sqm transit-oriented development that weaves together landscape, architecture, and cultural identity. Positioned at a strategic transportation nexus connecting highway, metro, and high-speed rail, Taichung D‑ONE is set to become a civic-commercial landmark. Beyond its department store and conference facilities, themed zones throughout the project create a more diverse and engaging urban destination.

Wuhan Alibaba Centre, China – Best Mixed-Use Project
Our latest collaboration with Alibaba brings 450,000sqm of smart, integrated space to central China. The development features twin towers (272.5m and 173m) with a six-storey retail podium, all inspired by the traditional ​“Kongming lock” with its intricate interlocking forms. This dynamic hub fuses talent, entrepreneurship, commerce, and lifestyle, creating versatile public spaces designed for the modern digital economy.

Winners will be revealed at the Gala Dinner on December 4^th at Rosewood Hong Kong, coinciding with the MIPIM Asia Summit on December 3^rd-4^th.

We’re honoured to be recognised alongside Asia’s finest developments and look forward to celebrating this milestone with our clients, partners, and the wider community.

Discover the full list of finalists: https://​awards​.mip​im​-asia​.com/​m​i​p​i​m​a​s​i​a​a​w​a​r​d​s​2​0​2​5​/​e​n​/​p​a​g​e​/​s​h​o​r​t​l​i​s​t​e​d​-​w​i​n​n​e​r​s​-2025

As Gulf markets navigate mixed performances amid easing U.S.-China trade tensions and tepid earnings, investors are closely watching the impacts on regional indices. In this environment, dividend stocks can offer a measure of stability and income potential, making them an attractive option for those seeking to balance risk with steady returns.

Click here to see the full list of 68 stocks from our Top Middle Eastern Dividend Stocks screener.

We’re going to check out a few of the best picks from our screener tool.

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Gulf Medical Projects Company (PJSC) operates hospitals in the United Arab Emirates and has a market cap of AED 1.44 billion.

Operations: Gulf Medical Projects Company (PJSC) generates revenue primarily from Health Services & Others, amounting to AED 711.55 million, and Investments, contributing AED 50.66 million.

Dividend Yield: 7.3%

Gulf Medical Projects Company offers a high dividend yield of 7.28%, placing it among the top 25% in the AE market. However, its dividends are not well covered by earnings, with a payout ratio of 106.2%. Despite recent earnings growth and cash flow coverage at an 84.6% cash payout ratio, dividend payments have been volatile over the past decade. The stock trades significantly below its estimated fair value but has experienced high price volatility recently.

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Delek Group Ltd. is an energy company involved in the exploration, development, production, and marketing of oil and gas both in Israel and internationally, with a market cap of ₪15.12 billion.

Operations: Delek Group’s revenue segments include the development and production of oil and gas assets in the North Sea, generating ₪9.45 billion, and oil and gas exploration and production in Israel and its surroundings, contributing ₪3.36 billion.

Dividend Yield: 6.2%

Delek Group’s dividend yield of 6.22% ranks in the top 25% of the IL market, yet its dividends are unreliable and volatile over the past decade. Despite a low cash payout ratio of 26.1%, indicating coverage by cash flows, earnings do not cover dividends due to a high payout ratio of 107.5%. The company’s net income has declined despite increased sales, and it faces significant debt levels while trading below estimated fair value.

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: I.D.I. Insurance Company Ltd. offers a range of insurance products and services to both individual and corporate clients in Israel, with a market cap of ₪2.88 billion.

Operations: I.D.I. Insurance Company Ltd. generates its revenue through the provision of diverse insurance products and services to both individual and corporate clients in Israel.

Dividend Yield: 6.7%

I.D.I. Insurance’s dividend yield of 6.74% is among the top 25% in the IL market, but its dividends have been volatile and unreliable over the past decade. The low payout ratio of 35.3% suggests earnings cover dividends, yet a high cash payout ratio of 264.1% indicates insufficient cash flow coverage. Despite recent earnings growth—net income rose to ILS 94.62 million for Q2—the dividend sustainability remains questionable due to these financial constraints.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ADX:GMPC TASE:DLEKG and TASE:IDIN.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Indonesian stocks may suffer outflows, according to Citigroup Inc., as MSCI Inc. flags potential changes to its index weightings for companies with certain shareholding structures.

The benchmark Jakarta Composite Index fell 1.9% on Monday and fluctuated on Tuesday, after the index provider sought feedback on how to estimate the free float of Indonesian securities, or the portion of shares available for trading in the open market. The change might reduce some companies’ weightings in key MSCI indexes.

(Bloomberg) — The record-setting advance in global equities took a breather in Asian trading, as investors braced for a flurry of earnings from megacap technology companies and policy announcements from major central banks this week.

MSCI’s Asia Pacific gauge dipped 0.1% as indexes in Japan and South Korea retreated from their all-time highs. An index in Shanghai broke above the psychological barrier of 4,000 for the first time in a decade. The moves came after US indexes had closed at all-time highs as Chinese and US trade negotiators lined up an array of diplomatic wins for Donald Trump and Xi Jinping to unveil at a summit this week.

“What we’re hoping is for some agreement with hard numbers,” Lorraine Tan, director of equity research for Asia at Morningstar, said in a Bloomberg TV interview. “We’re still going to be skeptical in effect that we do expect heightened risks from tariffs and geopolitics — there is no escape from that.”

Easing trade tensions have helped fuel a stock rally, while US companies have so far emerged largely unscathed by tariffs, protecting margins through price increases and cost cuts. That optimism faces a reality check this week as investors look to the Federal Reserve meeting for clues on the path of rate cuts, while major technology firms including Amazon.com Inc. and Microsoft Corp. reveal whether earnings momentum can be sustained.

On Wednesday and Thursday, five firms that account for about a quarter of the US benchmark — Microsoft Corp., Alphabet Inc., Meta Platforms Inc., Amazon.com and Apple Inc. — will report results. A gauge of the “Magnificent Seven” megacaps jumped 2.6% on Monday.

“With the Fed on track to cut rates, extending the run would appear to hinge on this week’s lineup of high-profile earnings releases,” said Chris Larkin at E*Trade from Morgan Stanley.

In other corners of the market, the yuan climbed to its strongest level in nearly a year, amid optimism over a potential China-US trade deal. A gauge of the dollar edged lower for a second day, while Treasuries were little changed. Gold held just below $4,000 an ounce as progress in trade talks sapped demand for haven assets.

The yen advanced to 152.24 a dollar Tuesday, outperforming its Group-of-10 peers, as markets welcomed supportive remarks from Japanese officials and cheered the outcome of a high-profile meeting between US and Japanese leaders in Tokyo.

What Bloomberg strategists say…

FX traders are reading it to be a reminder that the US administration would prefer a softer dollar. However, the Bank of Japan still needs to do their part this week and set up a rate hike for December. Otherwise USD/JPY could flip back to the 153 area, or higher.

— Mark Cranfield, Markets Live strategist. Click here for the full analysis.

Copper — a bellwether for global growth — advanced and traded roughly $60 shy of a record set last year as investors assessed the cooling of trade tensions between the US and China.

Technology stocks were in focus after Amazon.com planned to cut as many as 30,000 jobs, Reuters reported. Earlier, Qualcomm Inc. shares rose to their highest price in 15 months after unveiling chips and computers for the lucrative AI data center market, aiming to challenge Nvidia Corp. in the fastest-growing part of the industry.

On trade, Trump told reporters on Monday that “I really feel good” about a deal with China, after officials unveiled a slew of agreements to ease tensions.

While markets cheered the latest developments, some analysts cautioned the deal now teed up for Trump and Xi to sign in South Korea ignored thorny issues.

Fundamental fights over national security appeared untouched, they said, along with Trump’s stated core mission of rebalancing trade. Making that harder, Chinese investment into America remains heavily restricted.

“While these developments have lifted market spirits, analysts remain skeptical that the underlying issues — such as national security and tech competition — will be fully resolved,” said Fawad Razaqzada at City Index and Forex.com. “Nevertheless, traders have embraced the risk-on mood.”

Meanwhile, Trump hailed the US’s alliance with Japan, reaffirming ties with a longstanding partner and praising new Prime Minister Sanae Takaichi on her plans to ratchet up defense spending as the pair met in Tokyo. Trump and Takaichi signed a framework on critical minerals.

Takaichi is navigating implementation of a trade deal brokered under her predecessor that includes a nebulous pledge for Japan to fund $550 billion in US projects.

Corporate News:

Domino’s Pizza Enterprises Ltd. shares fell after the fast-food chain said it hasn’t received any takeover offer from buyout firm Bain Capital, refuting an earlier report that sent the stock surging. Nidec Corp. shares tumbled as much as their daily limit of 19% on Tuesday as the company was set to be removed from the Nikkei 225 Stock Average and was flagged for special oversight by the Tokyo Stock Exchange. CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a slowdown in its Seqirus unit. HSBC Holdings Ltd. reported third-quarter revenue that beat estimates, driven by its key wealth businesses, even as a $1.1 billion provision tied to the Bernard Madoff fraud cases weighed on earnings. Some of the main moves in markets:

Stocks

S&P 500 futures were unchanged as of 1:06 p.m. Tokyo time Nikkei 225 futures (OSE) fell 0.2% Japan’s Topix fell 0.6% Australia’s S&P/ASX 200 fell 0.3% Hong Kong’s Hang Seng was little changed The Shanghai Composite rose 0.2% Euro Stoxx 50 futures fell 0.2% Currencies

The Bloomberg Dollar Spot Index fell 0.1% The euro rose 0.1% to $1.1661 The Japanese yen rose 0.4% to 152.26 per dollar The offshore yuan rose 0.2% to 7.0967 per dollar The Australian dollar was little changed at $0.6562 Cryptocurrencies

Bitcoin fell 0.5% to $113,860.86 Ether fell 0.9% to $4,092.4 Bonds

The yield on 10-year Treasuries was little changed at 3.98% Japan’s 10-year yield declined 1.5 basis points to 1.650% Australia’s 10-year yield declined two basis points to 4.17% Commodities

West Texas Intermediate crude fell 0.1% to $61.24 a barrel Spot gold rose 0.1% to $3,987.86 an ounce This story was produced with the assistance of Bloomberg Automation.

–With assistance from Alex Gabriel Simon.

©2025 Bloomberg L.P.

Specialty

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

The Australian biotech company CSL has been delivered a “second strike” by shareholders over its executive pay plans, but has survived a push to spill its board.

Amid frustration over its depressed share price, the blood plasma therapy firm – a former commonwealth entity – saw more than 40% of votes cast against its executive pay plans at its annual general meeting in Melbourne on Tuesday.

The result was well above the 25% threshold required to trigger a “strike”, the company’s second in a row.

Despite hitting the two-strikes trigger – which opened the door for a board spill resolution – shareholders voted overwhelmingly against removing the board.

“We passed that hurdle,” said the CSL chair, Brian McNamee, in reaction to the spill vote.

The two-strikes rule is a federal government initiative, which began in 2011, designed to hold companies to account over excessive pay rates.

The shareholder unrest is linked to a perceived mismatch between the company’s performance and its high pay rates, with its shares down more than 35% this year. This includes a 15% sell-down on Tuesday after CSL reported an expected fall in US vaccination rates.

Guardian Australia reported earlier this month that CSL was among several major Australian companies that regularly spend more on bonuses for their chief executives than they pay in company tax in Australia.

The vaccine maker has been grappling with a decline in influenza vaccination rates in the US, which remain below pre-pandemic levels.

In the current flu season, CSL expects US vaccination rates to decline by 12% for the overall population, and by 14% for people over 65 years old, according to Morningstar.

McNamee said it was “remarkable” that flu vaccine rates were falling in the US after such a severe season last year.

“Remarkable, but it’s our reality,” McNamee said.

There has also been lingering shareholder resentment against CSL over the high price tag it paid for the Swiss iron deficiency group Vifor in 2022.

While CSL’s performance has wavered, the biotech continues to pay some of the highest executive rates in corporate Australia.

In its last 12-month reporting period, CSL’s chief executive, Paul McKenzie, earned $US6.06m ($9.2m). His predecessor, Paul Perreault, once earned more than $US45m in a single year due to various incentive schemes.

The company has consistently defended its pay rates, arguing that while it is headquartered in Australia, it must attract executives in a competitive global biotechnology market.